ANI Pharmaceuticals (NASDAQ:ANIP) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report published on Monday morning,Benzinga reports. They currently have a $94.00 price objective on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently commented on ANIP. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. Finally, StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $77.71.

ANI Pharmaceuticals Stock Down 5.5 %

ANIP opened at $58.46 on Monday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81. The business’s 50-day moving average price is $57.23 and its 200-day moving average price is $58.13. The company has a market cap of $1.23 billion, a P/E ratio of -106.29 and a beta of 0.74.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,300 shares of company stock worth $584,009 in the last 90 days. 12.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. US Bancorp DE raised its holdings in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares during the last quarter. KBC Group NV raised its holdings in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $166,000. Finally, HighTower Advisors LLC purchased a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $222,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.